title: Combining rosuvastatin with angiotensin-receptor blockers of different PPARγ-activating capacity: effects on high-density lipoprotein subfractions and associated enzymes.
abstract: The effects of combining angiotensin-receptor blockers of different peroxisome proliferator-activated receptor γ-activating capacity with rosuvastatin on high-density lipoprotein (HDL) subfractions and associated enzymes in patients with mixed dyslipidemia, hypertension, and prediabetes were assessed. Patients (n = 151) were randomly allocated to rosuvastatin (10 mg/d) plus telmisartan 80 mg/d (RT group, n = 52) or irbesartan 300 mg/d (RI group, n = 48) or olmesartan 20 mg/d (RO group, n = 51). Total and intermediate HDL cholesterol (HDL-C) levels did not change in any group. Large HDL-C increased, while small HDL-C decreased significantly in all the groups (P = not significant between the groups). The mass of HDL lipoprotein-associated phospholipase A2 (HDL-Lp-PLA2) and the activities of paraoxonase 1 remained unchanged in all the groups. However, HDL-Lp-PLA2 activity increased only in the RT group (+21.4%; P < .01 vs baseline) and did not change in the RI (-4.3%; P = .005 vs RT group) and RO (+3.2%; P = .01 vs RT) groups. In conclusion, only the combination of rosuvastatin with telmisartan increased the possibly antiatherosclerotic HDL-Lp-PLA2 activity.
authors.affiliation: Department of Internal Medicine, School of Medicine, University of Ioannina, Ioannina, Greece.
authors.forename: Christos V
authors.initials: CV
authors.lastname: Rizos
authors.affiliation: Department of Internal Medicine, School of Medicine, University of Ioannina, Ioannina, Greece vaglimp@yahoo.com.
authors.forename: Evangelos N
authors.initials: EN
authors.lastname: Liberopoulos
authors.affiliation: Laboratory of Biochemistry, School of Chemistry, University of Ioannina, Ioannina, Greece.
authors.forename: Kostas
authors.initials: K
authors.lastname: Tellis
authors.affiliation: Mid America Heart Institute, Saint Luke's Hospital, Kansas City, MO, USA Wegmans Pharmacy, Ithaca, NY, USA.
authors.forename: James J
authors.initials: JJ
authors.lastname: DiNicolantonio
authors.affiliation: Laboratory of Biochemistry, School of Chemistry, University of Ioannina, Ioannina, Greece.
authors.forename: Alexandros D
authors.initials: AD
authors.lastname: Tselepis
authors.affiliation: Department of Internal Medicine, School of Medicine, University of Ioannina, Ioannina, Greece.
authors.forename: Moses S
authors.initials: MS
authors.lastname: Elisaf
mesh_terms: D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase / Q000097:blood; D000368:Aged; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use*; D043303:Aryldialkylphosphatase / Q000097:blood*; D001562:Benzimidazoles / Q000627:therapeutic use; D001565:Benzoates / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D001713:Biphenyl Compounds / Q000627:therapeutic use; D008076:Cholesterol, HDL / Q000097:blood; D004359:Drug Therapy, Combination; D050171:Dyslipidemias / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D005464:Fluorobenzenes / Q000627:therapeutic use*; D006115:Greece; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D006973:Hypertension / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D007093:Imidazoles / Q000627:therapeutic use; D000077405:Irbesartan; D008075:Lipoproteins, HDL / Q000097:blood*; D008297:Male; D008875:Middle Aged; D047495:PPAR gamma / Q000819:agonists* / Q000378:metabolism; D011236:Prediabetic State / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D011743:Pyrimidines / Q000627:therapeutic use*; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides / Q000627:therapeutic use*; D000077333:Telmisartan; D013777:Tetrazoles / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D001562:Benzimidazoles; D001565:Benzoates; D015415:Biomarkers; D001713:Biphenyl Compounds; D008076:Cholesterol, HDL; D005464:Fluorobenzenes; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007093:Imidazoles; D008075:Lipoproteins, HDL; D047495:PPAR gamma; D011743:Pyrimidines; D013449:Sulfonamides; D013777:Tetrazoles; D000068718:Rosuvastatin Calcium; C437965:olmesartan; D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase; C526684:PLA2G7 protein, human; D043303:Aryldialkylphosphatase; C468406:PON1 protein, human; D000077405:Irbesartan; D000077333:Telmisartan
keywords: high-density lipoprotein cholesterol; irbesartan; lipoprotein-associated phospholipase A2; olmesartan; paraoxonase; rosuvastatin; telmisartan